Boomi’s Market Momentum Accelerates as Enterprises Standardize on Its AI Activation Platform
4.2.2026 16:00:00 EET | Business Wire | Press release
Boomi™, the leader in AI-driven automation, today announced that the company’s momentum in enterprise integration and agentic AI has reached a defining moment, driven by unmatched scale, independent analyst validation, proven customer outcomes, and ecosystem growth. With more than 30,000 customers worldwide — including over a quarter of the Fortune 500 — Boomi’s continued growth reflects the trust the world’s largest enterprises place in its platform.Today, customers rely on Boomi’s unique runtime architecture for mission-critical operations — including over 75,000 AI agents in production — executing billions of dollars in transactions with enterprise-grade reliability and resilience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204745523/en/
Boomi’s Market Momentum Accelerates as Enterprises Standardize on Its AI Activation Platform
“Boomi is experiencing the strongest momentum in its history,” said Steve Lucas, Chairman and CEO of Boomi. “Organizations are moving beyond AI experimentation and turning to Boomi to help them operationalize AI at enterprise scale. That momentum is reflected in our customer growth, where we have expanded our customer base by 50% in just over three years. Our platform innovations, strategic partnerships, and global customer base reflect a clear shift toward real-world outcomes, enabling businesses to unlock value, streamline operations, and build a trusted foundation for the future of AI-enabled automation.”
This adoption is reinforced by unprecedented third-party recognition. In 2025, Boomi was the only vendor named a Leader in both the Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS) and the Gartner® Magic Quadrant™ for API Management. In the iPaaS category, it marked the 11th consecutive time Boomi was positioned as a Leader. Boomi achieved another industry first with its inclusion as a Major Player in the IDC MarketScape: Worldwide Data Integration Software Platforms 2025 Vendor Assessment.1 And most recently, Boomi was designated an Exemplary Vendor in both the ISG Buyers Guide™ for Data Integration and the ISG Buyers Guide™ for Master Data Management. In these reports, Boomi earned multiple Leader placements across product capability, customer experience, and validation.
“The enterprise integration and automation market is reaching an inflection point as AI moves from experimentation to large-scale deployment,” said Shari Lava, Research Vice-President, AI and Automation, IDC. “As AI initiatives become embedded in mission-critical operations, buyers are looking beyond point solutions and increasingly favoring platforms that combine integration, automation, and governance at enterprise scale. Organizations are prioritizing proven platforms with demonstrated reliability, broad ecosystem support, and modern developer experiences — particularly those capable of supporting high-volume workloads, ensuring trust and compliance, and delivering measurable business outcomes. These characteristics are becoming foundational to the next phase of enterprise AI adoption.”
Setting the Standard for Trusted, Enterprise-Scale AI Adoption
As enterprises shift from AI pilots to production, Boomi continues to strengthen its competitive position through disciplined innovation and enterprise trust. Among the first vendors to achieve ISO/IEC 42001 certification for AI management — and the only provider in its sector compliant across all 16 key security standards — Boomi supports regulated, large-scale AI initiatives. Boomi further strengthened its AI compliance posture by officially listing ISO/IEC 42001 on the CSA STAR registry and achieving a current SecurityScorecard rating of 96. Boomi has also maintained the highest consistent SecurityScorecard rating among leading iPaaS providers, averaging 95+ for the past 18 months, reinforcing its commitment to industry-leading security and governance.
The company has also expanded its core platform through the strategic acquisitions of Rivery and Thru, Inc., enhancing real-time data ingestion and enterprise-grade managed file transfer capabilities that support higher-volume workloads and broaden Boomi’s addressable enterprise use cases.
Customer Growth and Impact
With adoption accelerating across global enterprises, Customers such as Australian Red Cross, Avalara, BNP Paribas, Chevron Federal Credit Union, Crane Worldwide Logistics, Lexitas, Moderna, Multiquip, NFI Industries, Quanta Services, Sandoz, Toyota Australia, University of Technology Sydney, and World Wide Technology are pushing the boundaries of what’s possible using Boomi to tackle critical business challenges and deliver measurable impact.
“As a company built on great-tasting products, innovation, and speed, transforming our IT services with AI is critical,” said Jeff Lischett, Global CIO, Tropicana Brands Group. “By using Boomi to connect our enterprise systems and automate key processes with greater intelligence, we’re shifting from reactive issue resolution to proactive operations—strengthening shipment and delivery execution and improving order processing performance.”
Product Innovation: Advancing the Enterprise Platform for Agentic Transformation
Boomi delivered a series of major platform innovations in 2025 that reflect the company’s focus on enabling trusted, governed, and production-ready AI across complex, hybrid environments:
- Boomi Agentstudio –Since its launch, Boomi Agentstudio, Boomi’s agent management platform (AMP), has seen rapid enterprise adoption as organizations scale agentic AI with built-in governance. More than 75,000 agents are now deployed in production, and partners have published hundreds of reusable agentic workflow assets through the Boomi Marketplace, accelerating time to value across real-world use cases.
- API Management and MCP Support - Boomi introduced comprehensive API management to help organizations securely expose, manage, and scale APIs alongside integrations and AI workflows. Boomi also broadened support for Model Context Protocol (MCP) to enable more flexible, context-aware agent interactions, while new innovations, such as Data Hub Command Center, strengthened centralized data governance, observability, and control.
- Boomi Data Integration and MFT - The acquisition of Rivery, now Boomi Data Integration, enhanced real-time data ingestion and analytics-ready pipelines, enabling customers to unify operational and analytical data at scale. Boomi’s acquisition of Thru, Inc. added enterprise-grade managed file transfer (MFT) capabilities, supporting secure, high-volume workloads — an expansion that has increased customer adoption by more than 270% following the acquisition. Additional innovations — including change data capture (CDC) ingestion for SAP — further expanded Boomi’s ability to support complex enterprise environments and modernization initiatives.
Together, these product advancements position Boomi as a foundational platform for organizations seeking to connect data, applications, APIs, and agents into a unified, governed system designed for scale, resilience, and measurable business impact.
Strategic Partnerships Expand Enterprise Success
In 2025, Boomi expanded its global partner ecosystem, deepening strategic collaborations with leading technology and services providers to help enterprises accelerate AI-driven transformation, including:
- AWS — Boomi and Amazon Web Services (AWS) entered into a multi-year Strategic Collaboration Agreement focused on helping enterprises build, monitor, and govern generative AI agent workflows. Together, the companies are enabling customers to accelerate SAP migrations, modernize hybrid environments, and deploy trusted, scalable AI solutions on AWS.
- ServiceNow — Boomi expanded its partnership with ServiceNow, announcing a strategic commitment to elevate customer experiences through AI-powered self-service solutions and intelligent workflows. As part of the expanded collaboration, the partnership has delivered additional capabilities within ServiceNow Workflow Data Fabric for connecting the whole enterprise, and now also includes Boomi Data Hub Command Center, a new module powered by ServiceNow workflows that strengthens data governance, visibility, and automation.
- DXC — In partnership with DXC Technology, Boomi established a Center of Excellence for Agentic AI to help organizations modernize legacy environments, unify systems, and accelerate adoption of agentic automation.
- EY — Boomi further strengthened its alliance with EY, expanding joint efforts to support large-scale enterprise modernization, data integration, and AI readiness initiatives.
Rapid Global and Regional Workforce Expansion
Over the past three years, Boomi has grown its global headcount by nearly 40% as the company continues to scale worldwide.
In Vancouver, Boomi has ramped operations from no local presence to a team of more than 250 employees, opening and expanding office space to support continued growth in the region.
Looking Ahead: 2026 Will Be the Year of AI Activation
As enterprises move beyond AI pilots toward production, Boomi believes 2026 will mark the shift from experimentation to activation. Competitive advantage will come not from investing in AI alone, but from embedding governed, production-ready intelligence into core systems, data, and workflows — separating organizations that deliver measurable outcomes from those still stuck in proof-of-concept.
“2026 will be the year organizations stop experimenting with AI and start activating it at scale,” said Lucas. “The winners won’t be the ones that invested the most, but the ones that built the right foundation, connecting data, systems, and intelligent agents with trust and governance at the core. This is the moment when AI moves from promise to performance, and Boomi is helping enterprises turn that potential into lasting business impact.”
Additional Resources
- Sign up to watch The Future of Enterprise Integration Webinar on Thursday, February 19, 2026
- Learn more about the Boomi Enterprise Platform
- Follow Boomi on X, LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the leader in AI-driven automation, enables organizations worldwide to connect everything, automate processes, and accelerate outcomes. The Boomi Enterprise Platform — including Boomi Agentstudio — unifies integration and automation along with data, API, and AI agent management, in a single, comprehensive solution. Trusted by over 30,000 customers and supported by a network of 800+ partners, Boomi is driving agentic transformation — helping enterprises of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com.
© 2026 Boomi, LP. Boomi, the ‘Boomi’ logo, the ‘B’ logo, and Boomiverse are registered trademarks of Boomi, LP or its subsidiaries or affiliates in the US and other countries. All rights reserved. Other names or marks may be the trademarks of their respective owners.
ServiceNow, the ServiceNow logo, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries.
| _______________________ |
1 IDC MarketScape: Worldwide Data Integration Software Platforms 2025 Vendor Assessment, Doc #US53001625, October 2025 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260204745523/en/
Contacts
Media Contact:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom